COVID-19 Impact on Global Non-oncology Biopharmaceuticals Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Biologics
  • 1.4.3 Biosimilars
• 1.5 Market by Application
  • 1.5.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2026
  • 1.5.2 Immunology
  • 1.5.3 Endocrinology
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Non-oncology Biopharmaceuticals Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Non-oncology Biopharmaceuticals Industry
    • 1.6.1.1 Non-oncology Biopharmaceuticals Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Non-oncology Biopharmaceuticals Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Non-oncology Biopharmaceuticals Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Non-oncology Biopharmaceuticals Market Perspective (2015-2026)
• 2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions
  • 2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Non-oncology Biopharmaceuticals Historic Market Share by Regions (2015-2020)
  • 2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Non-oncology Biopharmaceuticals Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Non-oncology Biopharmaceuticals Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Non-oncology Biopharmaceuticals Players by Market Size
  • 3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2015-2020)
  • 3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
  • 3.2.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2019
• 3.3 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
• 3.4 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
• 3.5 Date of Enter into Non-oncology Biopharmaceuticals Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2015-2020)
• 4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2021-2026)

5 Non-oncology Biopharmaceuticals Breakdown Data by Application (2015-2026)

• 5.1 Global Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)
• 5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 6.2 Non-oncology Biopharmaceuticals Key Players in North America (2019-2020)
• 6.3 North America Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 6.4 North America Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 7.2 Non-oncology Biopharmaceuticals Key Players in Europe (2019-2020)
• 7.3 Europe Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 7.4 Europe Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

8 China

• 8.1 China Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 8.2 Non-oncology Biopharmaceuticals Key Players in China (2019-2020)
• 8.3 China Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 8.4 China Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 9.2 Non-oncology Biopharmaceuticals Key Players in Japan (2019-2020)
• 9.3 Japan Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 9.4 Japan Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 10.2 Non-oncology Biopharmaceuticals Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 10.4 Southeast Asia Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

11 India

• 11.1 India Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 11.2 Non-oncology Biopharmaceuticals Key Players in India (2019-2020)
• 11.3 India Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 11.4 India Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Non-oncology Biopharmaceuticals Market Size (2015-2020)
• 12.2 Non-oncology Biopharmaceuticals Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Non-oncology Biopharmaceuticals Market Size by Type (2015-2020)
• 12.4 Central & South America Non-oncology Biopharmaceuticals Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview and Its Total Revenue
  • 13.1.3 Roche Non-oncology Biopharmaceuticals Introduction
  • 13.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Sanofi
  • 13.2.1 Sanofi Company Details
  • 13.2.2 Sanofi Business Overview and Its Total Revenue
  • 13.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
  • 13.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.2.5 Sanofi Recent Development
• 13.3 Johnson & Johnson
  • 13.3.1 Johnson & Johnson Company Details
  • 13.3.2 Johnson & Johnson Business Overview and Its Total Revenue
  • 13.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
  • 13.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.3.5 Johnson & Johnson Recent Development
• 13.4 Pfizer
  • 13.4.1 Pfizer Company Details
  • 13.4.2 Pfizer Business Overview and Its Total Revenue
  • 13.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
  • 13.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.4.5 Pfizer Recent Development
• 13.5 Novo Nordisk
  • 13.5.1 Novo Nordisk Company Details
  • 13.5.2 Novo Nordisk Business Overview and Its Total Revenue
  • 13.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
  • 13.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.5.5 Novo Nordisk Recent Development
• 13.6 Novartis
  • 13.6.1 Novartis Company Details
  • 13.6.2 Novartis Business Overview and Its Total Revenue
  • 13.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
  • 13.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.6.5 Novartis Recent Development
• 13.7 Merck
  • 13.7.1 Merck Company Details
  • 13.7.2 Merck Business Overview and Its Total Revenue
  • 13.7.3 Merck Non-oncology Biopharmaceuticals Introduction
  • 13.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.7.5 Merck Recent Development
• 13.8 Teva
  • 13.8.1 Teva Company Details
  • 13.8.2 Teva Business Overview and Its Total Revenue
  • 13.8.3 Teva Non-oncology Biopharmaceuticals Introduction
  • 13.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.8.5 Teva Recent Development
• 13.9 Eli Lilly
  • 13.9.1 Eli Lilly Company Details
  • 13.9.2 Eli Lilly Business Overview and Its Total Revenue
  • 13.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
  • 13.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.9.5 Eli Lilly Recent Development
• 13.10 Bristol-Myers Squibb
  • 13.10.1 Bristol-Myers Squibb Company Details
  • 13.10.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  • 13.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
  • 13.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 13.10.5 Bristol-Myers Squibb Recent Development
• 13.11 GlaxoSmithKline
  • 10.11.1 GlaxoSmithKline Company Details
  • 10.11.2 GlaxoSmithKline Business Overview and Its Total Revenue
  • 10.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
  • 10.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.11.5 GlaxoSmithKline Recent Development
• 13.12 UCB Pharma
  • 10.12.1 UCB Pharma Company Details
  • 10.12.2 UCB Pharma Business Overview and Its Total Revenue
  • 10.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
  • 10.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.12.5 UCB Pharma Recent Development
• 13.13 Amgen
  • 10.13.1 Amgen Company Details
  • 10.13.2 Amgen Business Overview and Its Total Revenue
  • 10.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
  • 10.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.13.5 Amgen Recent Development
• 13.14 AbbVie
  • 10.14.1 AbbVie Company Details
  • 10.14.2 AbbVie Business Overview and Its Total Revenue
  • 10.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
  • 10.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.14.5 AbbVie Recent Development
• 13.15 Takeda
  • 10.15.1 Takeda Company Details
  • 10.15.2 Takeda Business Overview and Its Total Revenue
  • 10.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
  • 10.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.15.5 Takeda Recent Development
• 13.16 AstraZeneca
  • 10.16.1 AstraZeneca Company Details
  • 10.16.2 AstraZeneca Business Overview and Its Total Revenue
  • 10.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
  • 10.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.16.5 AstraZeneca Recent Development
• 13.17 Mylan
  • 10.17.1 Mylan Company Details
  • 10.17.2 Mylan Business Overview and Its Total Revenue
  • 10.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
  • 10.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.17.5 Mylan Recent Development
• 13.18 LEO Pharma
  • 10.18.1 LEO Pharma Company Details
  • 10.18.2 LEO Pharma Business Overview and Its Total Revenue
  • 10.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
  • 10.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.18.5 LEO Pharma Recent Development
• 13.19 Boehringer Ingelheim
  • 10.19.1 Boehringer Ingelheim Company Details
  • 10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  • 10.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
  • 10.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.19.5 Boehringer Ingelheim Recent Development
• 13.20 Alexion Pharmaceuticals
  • 10.20.1 Alexion Pharmaceuticals Company Details
  • 10.20.2 Alexion Pharmaceuticals Business Overview and Its Total Revenue
  • 10.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
  • 10.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.20.5 Alexion Pharmaceuticals Recent Development
• 13.21 Elusys Therapeutics
  • 10.21.1 Elusys Therapeutics Company Details
  • 10.21.2 Elusys Therapeutics Business Overview and Its Total Revenue
  • 10.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
  • 10.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.21.5 Elusys Therapeutics Recent Development
• 13.22 Swedish Orphan Biovitrum
  • 10.22.1 Swedish Orphan Biovitrum Company Details
  • 10.22.2 Swedish Orphan Biovitrum Business Overview and Its Total Revenue
  • 10.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
  • 10.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.22.5 Swedish Orphan Biovitrum Recent Development
• 13.23 Biogen
  • 10.23.1 Biogen Company Details
  • 10.23.2 Biogen Business Overview and Its Total Revenue
  • 10.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
  • 10.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2015-2020)
  • 10.23.5 Biogen Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer